Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy
J Pang, N Ding, N Yin, Z Xiao - Scientific Reports, 2024 - nature.com
The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast
cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its …
cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its …
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
S Yildirim, A Dogan, G Akdag, Z Yüksel Yasar, H Bal… - Scientific Reports, 2024 - nature.com
Neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced, high-risk
breast cancer. Pathological complete response (pCR) improves survival. Peripheral blood …
breast cancer. Pathological complete response (pCR) improves survival. Peripheral blood …
[HTML][HTML] Development of a nomogram for predicting survival of breast cancer patients with neoadjuvant chemotherapy: a dynamic analysis for systemic inflammation …
W Huang, Z Xiong, W Zhong, C Zhang, J Feng… - Gland …, 2023 - ncbi.nlm.nih.gov
Background The systemic inflammation response index (SIRI) has been reported to
associate with survival outcomes in breast cancer patients. However, the effects of baseline …
associate with survival outcomes in breast cancer patients. However, the effects of baseline …
[HTML][HTML] Prognostic value of preoperative combined with postoperative systemic immune-inflammation index for disease-free survival after radical rectal cancer …
J Sun, R Yang, H Wu, L Li, Y Gu - Translational Cancer Research, 2024 - ncbi.nlm.nih.gov
Background Colorectal cancer (CRC) ranks highly in malignant tumor incidence and
mortality rates, severely affecting human health. The predictive value of the systemic …
mortality rates, severely affecting human health. The predictive value of the systemic …
Which Labarotory Index is Better for Predicting Survival and Pathological Response in Patients with Breast Cancer Receiving NACT?
S YILDIRIM, A DOGAN, G AKDAG, ZY YASAR… - 2024 - researchsquare.com
Objective: Neoadjuvant chemotherapy (NACT) is the standard treatment for locally
advanced, high-risk breast cancer. Pathological complete response (pCR) improves …
advanced, high-risk breast cancer. Pathological complete response (pCR) improves …